Areas of Expertise: Nonclinical Drug Discovery & Development; Preclinical Study Design & Execution; Drug Safety Assessment; Regulatory Toxicology; Global Regulatory Strategy & Submissions; Scientific & Strategic Leadership; Pharmaceutical Advisory & Mentorship

Dr.Krishna, a Diplomate of the American Board of Toxicology and Fellow of the Academy of Toxicological Sciences, is an accomplished pharmaceutical scientist, and independent consultant with over 35 years of experience in nonclinical drug discovery and development, safety assessment, and regulatory toxicology. He has held senior scientific and executive leadership positions at several reputed organizations including Pfizer, Abbott Laboratories, Supernus Pharmaceuticals, PAREXEL, and Inotiv. Additionally, Dr Krishna served in leadership roles at the Society of Toxicology including as the President (National Capital Area Chapter and Special Interest Group: ASIO) and on Journal Editorial Boards in this field. His expertise encompasses nonclinical study design and execution, safety evaluation, global regulatory strategies, and Good Laboratory Practice (GLP) compliance. He has contributed to numerous INDs, NDAs, and BLAs, as well as the development of marketed therapeutics including Lipitor, Neurontin, Lyrica, Humira, Oncaspar, Adagen, Oxtellar XR, Trokendi XR, Qelbree. Dr. Krishna actively contributes to scientific advisory activities, professional education, and mentorship. He continues to collaborate with global pharmaceutical sponsors and regulatory authorities, bringing extensive scientific insight, strategic leadership, and regulatory expertise to complex drug development programs.